Other Events ·
At its annual meeting on June 29, 2026, Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity…
IMUXImmunic, Inc.
At its annual meeting on June 29, 2026, Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan to increase authorized common stock by 6,000,000 shares, bringing the total to 8,644,887 shares. Shareholders also elected Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick as Class III Directors to serve until the 2029 annual meeting. Additionally, the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Immunic, Inc. is a biotechnology company.